Drug Trial Radar · NCT07930936
Immunotherapy and Irreversible Electroporation (IRE) in the Treatment of Locally Advanced Pancreatic Adenocarcinoma
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Jan 1, 2030
Study completion Jan 1, 2031
Sponsor
- Lead sponsor
- Robert C. MartinAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test the safety, tolerability, and preliminary effectiveness of the study drug, IP-001, in patients with locally advanced pancreatic cancer that is treated with IRE.
Conditions
- Locally Advanced Pancreatic Adenocarcinoma
Interventions
1.0% IP-001 for injectionDrug
Participants will receive intratumoral injection of 1% IP-001 (diluted to 1 mg/mL, up to 12 mL total) into and around the treated tumor and ablated area immediately following IRE
Irreversible ElectroporationProcedure
Participants will undergo IRE of the tumor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of IP-001 administered intratumorally following IRETime frame: Day 0 to 90 days after treatment or the start of subsequent anti-cancer therapy, whichever comes first
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Louisville
Louisville, Kentucky
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.